Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 7/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL414466 | 1.00 | CES1 (0.58) | CES1SRCCES2TSHRALDH1A1 | |
| SCHEMBL31097912 | 1.00 | CES1 (0.58) | CES1SRCCES2TSHRALDH1A1 | |
| SCHEMBL32681153 | 1.00 | CES1 (0.58) | CES1SRCCES2TSHRALDH1A1 | |
| SCHEMBL7684 | 1.00 | CES1 (0.58) | CES1SRCCES2TSHRALDH1A1 | |
| SCHEMBL637241 | 1.00 | CES1 (0.58) | CES1SRCCES2TSHRALDH1A1 | |
| SCHEMBL11542843 | 0.97 | CES1 (0.56) | CES1SRCCES2TSHRALDH1A1 | |
| Water SCHEMBL18124365 | 0.97 | CES1 (0.56) | CES1SRCCES2TSHRALDH1A1 | |
| Water SCHEMBL19283519 | 0.97 | CES1 (0.56) | CES1SRCCES2TSHRALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL11444696 | 0.97 | CES1 (0.56) | CES1SRCCES2TSHRALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL11444694 | 0.97 | CES1 (0.56) | CES1SRCCES2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103140486-B | Co-crystals and salts of CCR 3-inhibitors | 贝林格尔.英格海姆国际有限公司 | 2016-08-03 | — | — | CN | claimed |
| CN-101111478-B | Optical resolution method of amlodipine | SK CHEMICALS CO LTD | 2012-04-04 | — | — | CN | claimed |
| CN-101111478-A | Optical resolution method of amlodipine | SK CHEMICALS CO LTD (KR) | 2008-01-23 | — | — | CN | claimed |
| US-9408852-B2 | Method of lowering serum uric acid levels with (S)-tofisopam | PHARMOS CORPORATION (US) | 2016-08-09 | — | — | US | disclosed |
| CN-103140486-B | Co-crystals and salts of CCR 3-inhibitors | 贝林格尔.英格海姆国际有限公司 | 2016-08-03 | — | — | CN | disclosed |
| CN-103140486-A | Co-crystals and salts of CCR 3-inhibitors | BOEHRINGER INGELHEIM INT | 2013-06-05 | — | — | CN | disclosed |
| US-20130045966-A1 | Method of Lowering Serum Uric Acid Levels With (S)-Tofisopam | PHARMOS CORPORATION (US) | 2013-02-21 | — | — | US | disclosed |
| EP-1594509-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF IRRITABLE BOWEL SYNDROME AND NONULCER DYSPEPSIA | VELA ACQUISITION CORP (US) | 2010-08-11 | — | — | EP | disclosed |
| US-7745431-B2 | Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine and uses thereof | VELA ACQUISITION CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| EP-1755614-A4 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROPATHIC PAIN, FIBROMYALGIA AND CHRONIC FATIGUE SYNDROME | VELA PHARMACEUTICALS INC (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-1594509-A4 | COMPOSITIONS AND METHODS FOR TREATMENT OF IRRITABLE BOWEL SYNDROME AND NONULCER DYSPEPSIA | VELA ACQUISITION CORP (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20040157833-A1 | Pharmaceutical composition of 1- (3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine and uses thereof | VELA PHARMACEUTICALS, INC. | 2004-08-12 | — | — | US | disclosed |
| US-20040152695-A1 | Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine and uses thereof | VELA PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | disclosed |
| US-20040138210-A1 | Method of increasing neutrophil production using 2,3-benzodiazepines | VELA PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | disclosed |
| US-20040138209-A1 | Treatment of inflammatory disorders with 2,3- benzodiazepines | VELA PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2004050615-A2 | METHOD OF INCREASING NEUTROPHIL PRODUCTION USING 2,3-BENZODIAZEPINES | VELA PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050040-A2 | PHARMACEUTICAL COMPOSITION OF 1-(3,4-DIMETHOXYPHENYL)-4-METHYL-5-ETHYL-7-METHOXY-8-HYDROXY-5H-2,3-BENZODIAZEPINE AND USES THEREOF | VELA PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040106602-A1 | Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2004-06-03 | — | — | US | disclosed |
| US-20040106601-A1 | Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2004-06-03 | — | — | US | disclosed |
| US-6683072-B1 | EFFECTIVE LONG TERM ALLEVIATION | VELA PHARMACEUTICALS, INC. | 2004-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138209-A1 | Treatment of inflammatory disorders with 2,3- benzodiazepines | LTB4R2, LTB4R, GABRA4 | CES1 475/4885SRC 4785/4885CES2 848/4885 |
| US-20040157833-A1 | Pharmaceutical composition of 1- (3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine and uses thereof | GABRA4, GABBR1, GABRB2 | CES1 1420/4885SRC 3184/4885CES2 1310/4885 |
| US-20040106602-A1 | Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines | LTB4R2, LTB4R, PTGER4 | CES1 586/4885SRC 4724/4885CES2 1486/4885 |
| US-20040152695-A1 | Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine and uses thereof | GABRA4, GABRA2, GABRB2 | CES1 1410/4885SRC 2649/4885CES2 1548/4885 |
| US-20040106601-A1 | Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines | OPRL1, OPRD1, GABRR1 | CES1 342/4885SRC 4410/4885CES2 153/4885 |
| US-20040138210-A1 | Method of increasing neutrophil production using 2,3-benzodiazepines | GABRR1, GABRA1, GABRA3 | CES1 538/4885SRC 4806/4885CES2 210/4885 |
| US-20130045966-A1 | Method of Lowering Serum Uric Acid Levels With (S)-Tofisopam | ATIC, NPPA, XPNPEP1 | CES1 368/4885SRC 4626/4885CES2 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.